Janux Therapeutics, Inc.
JANX · NASDAQ
Bulios Fair Price
$13.74
17.2% downside
Current Price
$16.59
According to Bulios Fair Price, JANX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Janux Therapeutics is a biotechnology company focused on developing advanced therapeutic methods for cancer immunotherapy. The company specializes in utilizing its platform, which combines antibody technology with targeted therapeutic agents, to enhance the body's natural defense against cancer cells. Janux is developing various products, including bioconjugates, that aim to specifically target and destroy cancer cells while minimizing side effects on healthy tissues.
Sector
Healthcare
Industry
Biotechnology
CEO
David Alan Campbell
Employees
113
Headquarters
San Diego
Upcoming events
Earnings
Upcoming earnings report